Introduction
============

Dry eye disease (DED) is one of the most common ocular disorders, affecting 10--30% of the population \[[@r1]\]. Patients with DED experience visual disturbance, eye dryness, irritation, foreign body sensation, light sensitivity, itching, and even blindness \[[@r2],[@r3]\].

Recent studies have shown that DED is an inflammatory disease that shares similar characteristics with autoimmune diseases \[[@r4]-[@r6]\], although the exact pathogenesis of DED remains unclear. The immunological responses of the host have been supposed to play a critical role in the clearance of inflammation, including cytokine production, antigen participation, and receptor recognition, which depends on the host's genetic background.

Killer immunoglobulin-like receptor (KIR) molecules are encoded by the *KIR* gene family, which exhibit genetic variation in the number and type of the genes presented on a haplotype \[[@r7]\]. The *KIR* haplotypes can be resolved into two broad haplotypes termed A and B, which consist of four conserved framework genes, *KIR2DL4* (ID 3805; OMIM [604945](http://omim.org/entry/604945)), *3DL2* (ID 3812; OMIM [604947](http://omim.org/entry/604947)), *3DL3* (ID 115653; OMIM [610095](http://omim.org/entry/610095)), and *3DP1* (ID 548594; OMIM [610604](http://omim.org/entry/610604)). Haplotype B contains a variety of genes, including *KIR2DL2* (ID 3803; OMIM [604937](http://omim.org/entry/604937)), *2DL5* (ID 100125575; OMIM [605305](http://omim.org/entry/605305)), *2DS1* (ID 3806; OMIM [604952](http://omim.org/entry/604952)), *2DS2* (ID 100132285; OMIM [604953](http://omim.org/entry/604953)), *2DS3* (ID 3808; OMIM [604954](http://omim.org/entry/604954)), *2DS5* (ID 3810; OMIM [604956](http://omim.org/entry/604956)), or *3DS1 (*ID 3813; OMIM [604946](http://omim.org/entry/604946)), while haplotype A is characterized by the absence of all these genes. *KIR* genes are found in two adjacent clusters where the framework genes flank each cluster: *KIR3DL3* and *3DP1* flank the centromeric (*Cen*) cluster while *KIR2DL4* and *3DL2* flank the telomeric (*Tel*) cluster \[[@r7]\]. *KIR* gene motifs are defined based on the combination of *KIR* genes present in the *Cen* or *Tel* segment on the haplotype, and *KIR* haplotypes A and B, with different distributions among ethnic groups, have distinctive *Cen* and *Tel* gene-content motifs \[[@r8]-[@r10]\].

Natural killer (NK) cells are a vital component of the innate and adaptive immune systems, expressing several cell surface receptors (KIRs, C-type lectin superfamily receptors, and natural cytotoxicity receptors) \[[@r11]\]. NK cell activity is regulated by an extensive repertoire of regulatory receptors including the most polymorphic KIR family \[[@r12]\]. Several studies in *KIR* gene diversity were associated with infectious and noninfectious diseases \[[@r12],[@r13]\]. KIR molecules play an important role in anti-inflammation immunity by providing activating or inhibitory signals to regulate the activation of NK cells and T cell subsets \[[@r13],[@r14]\]. The *KIR* genotype with distinctive gene content from maternal and paternal haplotypes produces diversity among individuals, which may influence the individuals' immunity to different diseases. Interestingly, the associations between diseases and *KIR* genotypes have been observed in several clinical studies \[[@r14]-[@r16]\]. For example, individuals with *KIR* genotype A/A were reported to be relatively protected against psoriatic vulgaris and idiopathic bronchiectasis \[[@r14],[@r15]\], and individuals with genotype A/B were significantly more likely to remain seronegative among long-term HIV-exposed subjects than those with genotype A/A \[[@r16]\]. Previously, we showed that *KIR2DS2* was associated with the susceptibility to severe DED \[[@r17]\]. However, until now, the role of the overall *KIR* genotype in patients with DED has remained unclear. The aim of this study was to investigate the distribution of *KIR* genotypes and haplotypes in a Han Chinese population of 106 patients with DED and 220 healthy controls with polymerase chain reaction with sequence-specific primers (PCR-SSP).

Methods
=======

Subjects
--------

A total of 106 patients with DED, consisting of 47 men and 59 women, were recruited from the Ophthalmology Department and 220 unrelated healthy subjects from the health examination center of the 4^th^ People's Hospital of Jinan as a control group described by Ren et al. \[[@r17]\]. Of the 106 patients, 27 were classified with moderate DED and 79 (31 male, 48 female) with severe DED. These DED patients had no other diseases. Briefly, the patients with DED were diagnosed by Schirmer's I test, which was advised by the National Eye Institute workshop. A 35.5-mm filter paper strip was used to measure the amount of tears that were produced over a period of 5 min. More than 10-mm wetting of the filter paper was normal. Patients with moderate dry eyes had wetting values between 10 and 5 mm. Patients with severe dry eyes had wetting values of less than 5 mm. Meanwhile, healthy subjects had wetting values of more than 10 mm in Schirmer's I test. Valid informed consent was obtained from each participant, and this study was approved by the human ethics committee of the 4^th^ People's Hospital of Jinan. And the study adhered to the tenets of the Declaration of Helsinki and the ARVO statement on human subjects.

*KIR* genotyping
----------------

*KIR* genotyping was performed using PCR-SSP in all samples collected from the recruited subjects for the following 16 *KIR* genes: *2DL1--5*, *3DL1--3*, *2DS1--5*, *3DS1*, *2DP1*, and *3DP1*. The PCR sequence-specific polymorphism primers used for the detection of *KIR* genes, and the PCR amplification methods were previously described \[[@r17]\]. Briefly, 20--50 ng DNA was amplified in 10 ml volume containing 0.2 mM dNTP, 0.5U Taq DNA polymerase (Promega Corporation), 0.4 mM primers (except for *KIR2DS1*, 0.8 mM), and 1× PCR buffer. PCR amplificationwas carried out in a 9700 thermal cycler (PerkinElmer) under the following conditions: initial denaturing at 94 °C for 4min, followed by 30 cycles of 94 °C for 30 s, 65 °C for 30 s, and 72 °C for 90 s, plus a final extension at 72 °C for 10 min. Partial annealing temperatures were changed as follows: *KIR2DS2* (63 °C), *KIR2DS3* (63 °C), *KIR2DS4* (61 °C), and *KIR2DS5* (63 °C).

Genotype and haplotype analysis
-------------------------------

Each genotype was given the putative haplotype combination according to the model described by Hsu et al. \[[@r18]\]. In assigning genes to a specific haplotype, the following assumptions were made: 1) All haplotypes contained *KIR3DL3*, *2DL4*, and *3DL2*; 2) the haplotypes contained either *2DL2* or *2DL3*, but not both; and 3) the haplotypes contained either *3DP1* or *3DP1* variant (*3DP1v*), but not both \[[@r18]\]. In the assessment of the *KIR* haplotypes, haplotype B was defined by the presence of one or more of the following genes: *KIR2DL5*, *2DS1*, *2DS2*, *2DS3*, *2DS5*, and *3DS1*. Conversely, haplotype A was defined by the absence of all these genes \[[@r19]\]. Four conserved framework genes divide the *KIR* locus into similarly sized *Cen* and *Tel* segments that differ in gene content \[[@r8]\]. Genotypes for the *Cen* and *Tel* parts of the *KIR* locus were defined according to Cooley et al.'s description \[[@r8]\]. Briefly, *Cen*-A/A contains *2DL3* only, *Cen*-A/B contains *2DL3* with *2DS2* and/or *2DL2*, and *Cen*-B/B contains *2DS2* and/or *2DL2* but no *2DL3*, whereas *Tel*-A/A has *3DL1* and *2DS4* only, *Tel*-A/B has *3DL1* and *2DS4* with *3DS1* and/or *2DS1* and *Tel*-B/B lacks *3DL1* and/or *2DS4*.

Statistical analysis
--------------------

Genotype frequencies were determined by directly counting the number of individuals who were positive in some particular *KIR* phenotype specificity. Each genotype was given the putative haplotype combination according to the model described by Hsu et al. \[[@r18]\]. A chi-square was used to test for the statistical significance of the genotypes or haplotypes between the DED patient group and the healthy control group. P values less than 0.05 were regarded as statistically significant. The strength of the association was estimated by calculating the odds ratio (OR) and the 95% confidence interval (95% CI). Statistical analysis was performed using the [SPSS 15.0](http://www.spss.com) (SPSS Inc., Chicago, IL) software package. Bonferroni correction for multiple testing was applied in the comparison of the genotype and haplotype frequencies between the two groups. The corrected p values (*P*c) are shown in the tables.

Results
=======

*KIR* genotype frequencies in control subjects and patients
-----------------------------------------------------------

In our study, all tested *KIR* genes were detected in the healthy control and DED patient groups. Framework genes (*KIR2DL4*, *3DL2*, *3DL3*, and *3DP1*) were observed in all individuals. All *KIR* genotypes and putative haplotypes were determined according to Hsu et al.'s description \[[@r18]\].

In this study, no significant differences in the frequencies of the *KIR* genotypes and haplotypes were found between the patients with moderate DED and the healthy controls with the chi-square analysis (data not shown). However, certain *KIR* genotypes and haplotypes were associated with increased or reduced risk of severe DED ([Table 1](#t1){ref-type="table"} and [Table 2](#t2){ref-type="table"}). Twenty-three *KIR* genotypes were observed in both groups, including ten new genotypes of NF1-NF10, which has not been observed in Caucasians thus far \[[@r18]\]. Among these genotypes, 20 were determined in healthy controls and 21 in patients with DED ([Table 1](#t1){ref-type="table"}). In the healthy controls, the three *KIR* genotypes with higher frequencies in rank order were AJ (37.73%), AH (11.36%), and AF (10.45%). In the patients with DED, genotypes AJ (27.85%), G (13.92%), and P (10.12%) were the three higher genotypes. Genotype G was associated with increased risk of DED, and the OR and 95% CI were 2.58 and 1.10--6.02, respectively. However, the frequency of genotype G was not statistically significant between the two groups after the Bonferroni correction was applied for multiple testing. The other *KIR* genotypes did not show any associations between the two groups.

###### The frequencies of *KIR* genotype in healthy controls and DED patients.

  Genotype   Haplotype   Healthy controls   DED patients   OR(95%CI)   p value   *Pc* (n=23)                   
  ---------- ----------- ------------------ -------------- ----------- --------- ------------------- --------- --------
  E          1,3         2                  0.91           1           1.27      1.40(0.13--15.63)   0.785     
  F          1,4         3                  1.36           2           2.53      1.88(0.31--11.46)   0.487     
  G          4,5         13                 5.91           11          13.92     2.58(1.10--6.02)    0.025\*   ﹥0.05
  H          2,4         5                  2.27           3           3.8       1.70(0.40--7.27)    0.471     
  I          5,8         1                  0.45           1           1.27      2.81(0.17--45.43)   0.448     
  M          2,8         2                  1.04           2           2.53      2.83(0.39--20.45)   0.282     
  P          2,17        22                 10             8           10.12     1.01(0.43--2.38)    0.974     
  AE         1,6         8                  3.64           2           2.53      0.69(0.14--3-31)    0.64      
  AF         1,2         23                 10.45          6           7.59      0.70(0.28--1.80)    0.461     
  AG         1,1         9                  4.09           3           3.8       0.93(0.24--3.51)    0.909     
  AH         2,5         25                 11.36          6           7.59      0.64(0.25--1.63)    0.346     
  AI         1,5         16                 7.27           4           5.06      0.68(0.22--2.10)    0.5       
  AJ         2,2         83                 37.73          22          27.85     0.64(0.36--1.12)    0.115     
  NF1        2,9         1                  0.45           1           1.27      2.81(0.17--45.43)   0.448     
  NF2        4,13        1                  0.45           1           1.27      2.81(0.17--45.43)   0.448     
  NF3        2,6         1                  0.45           0           0         \-                  0.548     
  NF4        4,8         1                  0.45           1           1.27      2.81(0.17--45.43)   0.448     
  NF5        2,11        2                  0.91           0           0         \-                  0.395     
  NF6        2,23        0                  0              1           1.27      \-                  0.095     
  NF7        6,6         0                  0              1           1.27      \-                  0.095     
  NF8        1,4         0                  0              1           1.27      \-                  0.095     
  NF9        ?,?         1                  0.45           1           1.27      2.81(0.17--45.43)   0.448     
  NF10       ?,?         1                  0.45           1           1.27      2.81(0.17--45.43)   0.448     

+, positive numbers; gf, genotype frequency; OR, odds ratio; 95% CI, 95% confidence interval; \*, indicates statistical significance (p\<0.05) according Chi Square analysis; *Pc*, corrected p value after Bonferroni correction; ?, unclassed haplotype.

###### The frequencies of *KIR* haplotypes in healthy controls and DED patients.

  Haplotype   Healthy controls   DED patients   OR(95%CI)   p value   *P~C~* (n=13)                 
  ----------- ------------------ -------------- ----------- --------- ------------------- --------- --------
  1           70                 15.91          22          13.92     0.86 (0.51--1.44)   0.553     
  2           247                56.14          71          44.94     0.64(0.44--0.92)    0.016\*   ﹥0.05
  3           2                  0.45           1           0.63      1.40(0.13--15.49)   0.786     
  4           23                 5.23           19          12.03     2.48(1.31--4.69)    0.004\*   ﹥0.05
  5           55                 12.5           22          13.92     1.13(0.67--1.93)    0.647     
  6           9                  2.05           4           2.53      1.24(0.38--4.10)    0.719     
  8           4                  0.91           4           2.53      2.83(0.70--11.46)   0.128     
  9           1                  0.23           1           0.63      2.80(0.17--44.97)   0.449     
  11          2                  0.45           0           0         \-                  0.396     
  13          1                  0.23           1           0.63      2.80(0.17--44.97)   0.449     
  17          22                 5              8           5.06      1.01(0.44--2.32)    0.975     
  23          0                  0              1           0.63      \-                  0.095     
  ?           4                  0.91           4           2.53      2.83(0.70--11.46)   0.128     

+, positive numbers; hf, haplotye frequency; OR, odds ratio; 95% CI, 95% confidence interval; \*, indicates statistical significance (p\<0.05) according Chi Square analysis; *Pc*, corrected p value after Bonferroni correction; ?, unclassed haplotype.

*KIR* haplotype frequencies in control subjects and patients
------------------------------------------------------------

In this study, all 23 *KIR* genotypes were resolved into corresponding pairs of haplotypes ([Table 2](#t2){ref-type="table"}). There were 16 different haplotypes of which haplotype 2 was the most common (56.14%), followed by haplotype 1 (15.91%) and 5 (13.92%) in the healthy controls and the patients with DED. Haplotype 4 was associated with increased risk of DED, and the OR and 95% CI were 2.48 and 1.31--4.69, respectively; while haplotype 2 appeared to have an inverse association with the disease (OR, 0.64; 95% CI, 0.44--0.92). However, the frequencies of haplotypes 4 and 2 were not statistically significant between the two groups after the Bonferroni correction was applied for multiple testing. The other *KIR* haplotypes did not show any associations between the two groups.

The distributions of *KIR* haplotype A and B are shown in [Table 3](#t3){ref-type="table"}. The frequency of haplotype A was higher than haplotype B in the healthy controls and the patients with DED. Genotype B/B was associated with increased risk of DED, and the OR and 95% CI were 2.352 and 1.09--5.10, respectively. Interestingly, when compared the distributions of the *Cen* and *Tel* segments of the *KIR* genotype in the two groups ([Table 4](#t4){ref-type="table"}), *Cen-*B/B was also associated with increased risk of DED (OR, 2.380; 95% CI, 1.03--5.49). However, the frequencies of genotype B/B and *Cen-*B/B were not statistically significant between the two groups after the Bonferroni correction was applied for multiple testing. The other *Cen* and *Tel* motifs of the *KIR* genotypes did not show any associations between the two groups.

###### The frequencies of *KIR* genotypes A/A, A/B and B/B and haplotypes A and B, observed in healthy controls and DED patients.

  Genotyping       Healthy controls   DED     patients   OR(95%CI)   p value            *P~C~*    
  ---------------- ------------------ ------- ---------- ----------- ------------------ --------- --------
  KIR genotypes    gf                         gf                                        (n=3)     
  A/A              116                52.73   35         44.3        0.71(0.43--1.20)   0.199     
  A/B              87                 39.55   31         39.24       0.99(0.58--1.67)   0.962     
  B/B              17                 7.73    13         16.46       2.35(1.09--5.10)   0.027\*   ﹥0.05
  KIR haplotypes   hf                         hf                                        (n=2)     
  A                319                72.5    101        63.92       0.67(0.46--0.98)   0.043\*   ﹥0.05
  B                121                27.5    57         36.08       1.49(1.01--2.19)   0.043\*   ﹥0.05

+, positive numbers; gf, genotype frequency; hf, haplotye frequency; OR, odds ratio; 95% CI, 95% confidence interval; \*, indicates statistical significance (p\<0.05) according Chi Square analysis; *Pc*, corrected p value after Bonferroni correction; ?, unclassed haplotype.

###### The frequencies of *KIR* centromeric (*Cen*) and telomeric (*Tel*) gene content motifs in healthy controls and EDE patients.

  Motifs^\#^                                   Healthy controls   DED patients   OR (95% CI)   p value   *P~C~* (n=6)                 
  -------------------------------------------- ------------------ -------------- ------------- --------- ------------------ --------- --------
  Centromeric (*2DS2*, *2DL2*, *2DL3*)                                                                                                
  Cen-A/A                                      163                74.09          56            70.89     0.85(0.48--1.51)   0.581     
  Cen-A/B                                      43                 19.55          12            15.19     0.74(0.37--1.48)   0.391     
  Cen-B/B                                      14                 6.36           11            13.92     2.38(1.03--5.49)   0.037\*   ﹥0.05
  Telomeric (*3DL1*, *3DS1*, *2DS1*, *2DS4*)                                                                                          
  Tel-A/A                                      149                67.73          51            64.56     0.87(0.51--1.49)   0.608     
  Tel-A/B                                      38                 17.27          17            21.52     1.31(0.69--2.49)   0.403     
  Tel-B/B                                      33                 15             11            13.92     0.92(0.44--1.91)   0.817     

\#: KIR centromeric (Cen) and telomeric (Tel) gene content motifs were defined according to the description of Cooley et al. \[[@r8]\]. Briefly, Cen-A/A contains *2DL3* with *2DS2* and/or *2DL2*, and Cen-B/B contains *2DS2* and/or *2DL2* but no *2DL3*, whereas Tel-A/A has *3DL1* and *2DS4* only, Tel-A/B has *3DL1* and *2DS4* with *3DS1* and/or *2DS1* and Tel-B/B lacks *3DL1* and/or *2DS4*. +, positive numbers; gf, genotype frequency; OR, odds ratio; 95% CI, 95% confidence interval; \*, indicates statistical significance (p\<0.05) according Chi Square analysis; *Pc*, corrected p value after Bonferroni correction; ?, unclassed haplotype.

Discussion
==========

The *KIR* gene system spans a region of about 150 kb on chromosome 19 \[[@r11]\]. The number and type of *KIR* genes arranged on the haplotypes vary greatly, which produces substantial differences in *KIR* gene content among individuals \[[@r7]\]. Genetic diversity within the *KIR* locus can moderate the NK cells and T cell subset responses to a diverse array of diseases and thus suggests that *KIR* diversity may influence susceptibility or resistance to different diseases \[[@r20]\]. Recent studies showed that *KIR* genotypes are associated with autoimmune diseases such as idiopathic bronchiectasis \[[@r15]\] and psoriasis vulgaris \[[@r14]\] and microbial pathogen diseases caused by hepatitis B virus \[[@r21]\], Ebola virus \[[@r22]\], and HIV \[[@r16]\]. However, little is known about the association of *KIR* genotypes with DED, which is characterized by sustained inflammation on the ocular surface. Interestingly, this is the first study to analyze *KIR* genotypes associated with DED.

In our study, patients with DED and healthy controls were identified as having *KIR* genotype A/A, A/B, or B/B based on the multiple *KIR* genes the individuals possessed. Similar distributions of *KIR* genotypes were observed between the two groups ([Table 3](#t3){ref-type="table"}). Interestingly, individuals with genotype B/B had an increased risk of severe DED, which was consistent with, to some extent, our previous report that *KIR2DS2* was associated with susceptibility to DED \[[@r17]\] since genotype B/B contains *KIR2DS2*. It was similar to the results that genotypes with haplotype B were found to be increased in Japanese psoriasis vulgaris cases \[[@r14]\]. The structurally distinctive characteristic of haplotype B is the multiplicity of activating *KIRs* that might increase chances of accidental activation of immunocytes over the threshold. Moreover, this inaccurate activation would occur especially in patients who do not possess the proper combinations of inhibitory *KIR*s \[[@r14]\]. Recent data supported the hypothesis that DED is a localized autoimmune disease resulting from the imbalance between protective immunoregulatory and proinflammatory mechanisms \[[@r6]\]. Combined with our data, these findings supported previously proposed models of *KIR*-mediated autoimmunity \[[@r23]\].

Dividing these *KIR* haplotypes into the *Cen* and *Tel* motifs showed that homozygosity for *Cen-*B/B was also associated with increased risk of DED ([Table 4](#t4){ref-type="table"}). Interestingly, it was recently shown that *Cen*-B/B was associated with a lower risk of relapse after unrelated transplantation for acute myelogenous leukemia \[[@r8]\]. These data suggested that individuals with the *Cen*-B/B motif might generate different immune responses to different diseases.

We further refined *KIR* genotypes \[[@r18]\] to analyze the association between patients with DED and the healthy controls. In our study, ten new genotypes NF1--10 that have not been observed in Caucasians thus far were identified \[[@r18]\]. The distinctive distributions of the *KIR* genotypes between Han Chinese and Caucasian populations suggested the role of the natural selection of certain genes over the others. Interestingly, our data in [Table 1](#t1){ref-type="table"} and [Table 2](#t2){ref-type="table"} show that genotype G and haplotype 4 were associated with increased risk of DED, whereas haplotype 2 appeared to have an inverse association with the disease. These data suggested that different *KIR* genes within a genotype/haplotype might use the combinations of synergistic receptors to mediate different natural cytotoxicity here. Lu et al. \[[@r24]\] reported that individuals with genotype M or FZ1 or haplotype 4 had an increased risk of hepatitis B virus infection, whereas individuals with genotype AH or haplotype 5 facilitated the clearance of the hepatitis B virus. These data suggested that different *KIR* genotypes/haplotypes might contribute to the different immune responses to autoimmune and virus infectious diseases and that certain *KIR* gene combinations could provide an immune microenvironment to get rid of or be susceptible to different diseases.

All frequencies of these *KIR* genotypes and haplotypes were no longer significant between the healthy controls and the patients with DED after the Bonferroni correction analysis. The Bonferroni correction is a critical statistical method for mitigating the risk of making false-positive conclusions, and appropriate use can ensure the integrity of studies in which a large number of significance tests are used, although it tends to be a bit too conservative and increases the risk of generating false negatives \[[@r25]\].

Our findings might help develop biomarkers to monitor the ocular surface inflammatory status and provide a new interesting therapeutic strategy for considering the molecular basis of DED, which will not only improve our knowledge to fully understand the mechanisms that lead to DED but also provide directions for developing effective and safe anti-inflammatory treatments that will be beneficial for patients with DED.

In conclusion, our study showed that *KIR* genotype G, haplotype 4, and *Cen*-B/B were possibly associated with increased risk of DED, whereas haplotype 2 was possibly associated with a reduced risk of DED in a Han Chinese population. These studies should be subjected to multivariate analysis and repeated in patients of other ethnic origins from the same and different regions.

The authors thank Dr. Roberta Greenwood for critically reading and improving the English manuscript. This work was supported by Shandong Province Young and Middle-Aged Scientists Research Awards Fund (BS2011SW044), Medicine and Health Science and Technology Development Planning Projects of Shandong Province (2013WS0170).
